A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

This study was designed to compare the efficacy and safety of YL201 with Investigator's choice of chemotherapy in subjects with recurrent or metastatic nasopharyngeal carcinoma who have failed prior PD-(L)1 inhibitor and at least two lines of chemotherapy.

Trial Details

NCT ID
NCT06629597
Phase
PHASE3
Sponsor
MediLink Therapeutics (Suzhou) Co., Ltd.
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • YL201
  • Docetaxel
  • Capecitabine
  • Gemcitabine
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Voluntarily sign a written informed consent form (ICF).
  • Aged ≥18 years and ≤75 years, male or female.
  • ECOG performance status score of 0 or 1.
  • Life expectancy ≥ 3 months.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →